Back to medical news
MedPage Today
Ocular Myasthenia Gravis Scores Improve With Subcutaneous Treatment
October 4, 2026
Original source summary
(MedPage Today) -- Subcutaneous efgartigimod PH20 (Vyvgart Hytrulo) met the primary endpoint in the phase III ADAPT OCULUS trial of people with ocular myasthenia gravis show, interim data showed. At 4 weeks, ocular myasthenia gravis patients treated...
Verbatim from MedPage Today's own feed — "Ocular Myasthenia Gravis Scores Improve With Subcutaneous Treatment"
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news